Jasper Therapeutics, Inc.
JSPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $55,821 | $51,785 | $34,627 | $25,421 |
| G&A Expenses | $20,418 | $17,076 | $16,569 | $11,412 |
| SG&A Expenses | $20,418 | $17,076 | $16,569 | $11,412 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $76,239 | $68,861 | $51,196 | $36,833 |
| Operating Income | -$76,239 | -$68,861 | -$51,196 | -$36,833 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,970 | $4,396 | $13,511 | $6,196 |
| Pre-Tax Income | -$71,269 | -$64,465 | -$37,685 | -$30,637 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$71,269 | -$64,465 | -$37,685 | -$30,637 |
| % Margin | – | – | – | – |
| EPS | -4.89 | -6.18 | -10.33 | -26.89 |
| % Growth | 20.9% | 40.2% | 61.6% | – |
| EPS Diluted | -4.89 | -6.18 | -10.33 | -26.89 |
| Weighted Avg Shares Out | 14,584 | 10,439 | 3,648 | 1,139 |
| Weighted Avg Shares Out Dil | 14,585 | 10,439 | 3,648 | 1,139 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,058 | $5,199 | $701 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,373 | $1,108 | $975 | $377 |
| EBITDA | -$74,866 | -$67,753 | -$50,221 | -$36,456 |
| % Margin | – | – | – | – |